Saad Z. Usmani, MD

In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety and efficacy findings for this oral therapy in patients with heavily pretreated, late-relapsed multiple myeloma.

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the specific patient subgroups for whom autologous transplant remains the best course of action for.

Saad Z. Usmani, MD, MBA, FACP, FASCO, delves into the development of new treatments for patients with multiple myeloma.

The depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.

Saad Usmani, MD, speculates on the current progress in treating multiple myeloma, while providing a glimpse into the future of cutting-edge treatments.

Saad Usmani, MD, reflects on the impact the coronavirus pandemic has had on his practice and the treatment of patients with multiple myeloma overall.

The MAIA & PEGASUS Trial and Managing Patients Receiving DRd

Saad Usmani, MD, analyzes the efficacy and safety data results from the phase 3 MAIA study.

Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma and describes the patient’s current prognosis.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.

Saad Z. Usmani, MD, discusses the phase 2 SWOG 1211 trial investigating bortezomib, lenalidomide, and dexamethasone with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how to manage early relapse in multiple myeloma.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, highlights some of the ongoing studies presented at the 2017 ASH Annual Meeting.

Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.

Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.